The systemic administration of interleukin-2 (lL-2) can lead to significant antitumor responses in some patients with metastatic cancer in whom standard therapy has failed. A limitation of this immunotherapy is the toxicity associated with lL-2 infusion. To assess toxicity, we determined aspartate aminotransferase (AST; EC 2.6.1.1), alanine aminotransferase (ALT; EC 2.6.1.2), gamma-glutamyltransferase (GGT; EC 2.3.2.2), lactate dehydrogenase (LD; EC 1.1.1.27), alkaline phosphatase (ALP; EC 3.1.3.1), creatine kinase (CK; EC 2.7.3.2), total bilirubin (TBI), direct bilirubin (DBI), creatinine, urea nitrogen, and C-reactive protein in serum from 21 patients before and during five consecutive days of IL-2 treatment. Ten patients were followed for an additional five days after the end of lL-2 therapy. The lL-2 infusion caused liver toxicity and prerenal azotemia, as evidenced by significant increases (P <0.05) of all analytes except CK by day 1. There was a progressive increase in the results (except CK) for these tests until IL-2 treatment was stopped. Seven tests related to liver function (AST, ALT, GGT, LD, ALP, DBI, and TBI) showed increases, but the test results indicated significant improvement and moved toward the baseline value five days after the end of lL-2 therapy. Concentrations of creatinine and urea nitrogen in serum were normal three days after the cessation of IL-2 therapy. 
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Materials and Methods

Patient population:
We studied 21 patients with metastatic cancer, in whom standard therapy had faile4. Twelve patients had malignant melanoma, six had renal-cell carcinoma, and three had colon cancer. Signed informed consent was obtained from all of the patients before entry into the significance of the difference from baseline concentration (day 0) with results from days after IL-2 administration.
Results
Liver function: Figure 1 and Table 1 show the changes and DBIiTBI continued to increase over the five days of IL-2 treatment. The peak concentration for all seven analytes occurred close to the end of IL-2 treatment (day 0 vs day 5; P <0.0005, Table 1 ). The results for the seven liver-function tests progressed toward the baseline value after discontinuation of IL-2 infusion. However, all analytes were still significantly greater at day 10 than at day 0 (Table 1) .
Renal function: Serum creatinine and urea nitrogen concentrations before IL-2 treatment were 11.3 ± 0.07 mg/L (99.9 ± 0.6 molJL) and 151 ± 10 mgfL (2.51 ± 0.17 mniol/L), respectively (Table 1) . Both increased significantly one day after IL-2 administration (P <0.05), continued to increase thereafter, and reached a plateau at about day 5 at about double the baseline concentration (P <0.005; Figure 1 and Table 1 ). The urea nitrogenlcreatinine ratio increased by a factor of 1.8 after five days of IL-2 therapy. The creatinine and urea nitrogen concentrations from day 8 through day 10 were not significantly different from the baseline concentrations (P >0.05). Acute-phase protein: CRP showed a significant increase at day 1 (P <0.005) of treatment. The peak increase (7.8 times the baseline) occurred at day 3. However, one day after discontinuation of IL-2 (day 6) and thereafter, the CRP concentration did not differ significantly from the baseline value (Figure 1 ).
Creatine kinase: The results for creatine kinase differed from the other enzymes: it peaked earlier (day 2) and showed no significant increases from the baseline activity during the study.
Discussion
IL-2-based immunotherapy has proven useful in some patients with advanced cancer in whom standard therapy has failed.
The major obstacle of this regimen is the toxicity, associated primarily with IL-2 administration.
Our previous observations had suggested that most of the toxicity was attributable to the vascular leak syndrome, which was associated with substantial fluid retention and respiratory distress (10). The systemic IL-2 infusion caused immediate liver toxicity and prerenal azotemia, as shown by a significant increase (P <0.05) in the results of the biochemical tests for these functions. The abnormalities of these functions showed progressive increases, peaking near the end of IL-2 therapy (day 5). These data suggest that the toxicity is related to the cumulative dose of IL-2 over consecutive days of therapy.
The nature of the hepatic dysfunction is not entirely clear and may have several causes. The increase in aminotransferases, alkaline phosphatase, and total bilirubin, of which about 75% was direct bilirubin, was consistent with intrahepatic cholestasis. eemTcDisofenin scans performed in patients receiving IL-2 treatments showed normal uptake of tracer by the liver but a markedly delayed excretion into the biliary tree, gall bladder, and small bowel ( 
IL-6 production (7).
CRP is synthesized mainly in hepatocytes, the rate of synthesis being directly related to the duration and the extent of the inflammation in vivo. In view of the short half-life of CRP (approximately 8.9 h), the post-inflammatory elimination of CRP is equally rapid (19), and probably explains why the CRP concentration did not differ significantly from the baseline value one day after cessation of IL-2 therapy.
Clinical and laboratory information indicates that none of the patients had a myocardial infarction during the study. No clinical symptoms of myocardial infarction were reported for any of the patients, and mean CK activity did not increase significantly from the baseline. Thus, myocardial infarction was not a factor affecting our results.
